Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia
NCT05610280 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 21, 2022
- Completion date
- June 9, 2025
- Enrollment
- 1,478 (actual)
- Sites
- 168
Conditions
As the registry lists them; a condition with its own page is linked.